Drug Interactions between Ozempic and thyroid desiccated
This report displays the potential drug interactions for the following 2 drugs:
- Ozempic (semaglutide)
- thyroid desiccated
Interactions between your drugs
thyroid desiccated semaglutide
Applies to: thyroid desiccated and Ozempic (semaglutide)
MONITOR: The efficacy of semaglutide may be diminished by thyroid hormones. These drugs may interfere with blood glucose control. Additionally, concomitant administration of oral levothyroxine and semaglutide may result in increased levothyroxine exposure. In a controlled study with healthy volunteers, a 33% increase in total T4 exposure was observed when levothyroxine and oral semaglutide were coadministered, but levothyroxine peak plasma concentration (Cmax) was unaffected. The proposed mechanism is due to delayed gastric emptying caused by semaglutide leading to increased levothyroxine absorption. Clinical data with semaglutide and other thyroid hormones are unavailable.
MANAGEMENT: Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of thyroid hormones, and the dosage of semaglutide adjusted as necessary. Increased clinical monitoring of thyroid parameters should also be considered when treating patients with both semaglutide and oral levothyroxine. Administer other oral medications, including thyroid hormones at least 30 minutes after oral semaglutide to ensure medication efficacy.
References (12)
- (2023) "Product Information. Ozempic (semaglutide)." Novo Nordisk Pharmaceuticals Inc
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Pharmaceuticals Inc
- (2024) "Product Information. Wegovy (0.25 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc
- (2024) "Product Information. Ozempic (semaglutide)." Novo Nordisk Canada Inc
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Canada Inc
- (2024) "Product Information. Wegovy (semaglutide)." Novo Nordisk Canada Inc
- (2024) "Product Information. Ozempic (semaglutide)." Novo Nordisk Ltd
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Ltd
- (2024) "Product Information. Wegovy FlexTouch (semaglutide)." Novo Nordisk Ltd
- (2024) "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Pty Ltd
- (2024) "Product Information. Wegovy Flextouch (0.25 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Pty Ltd
- Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Baekdal TA (2021) "Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-cente" Expert Opin Drug Metab Toxicol, 17, p. 1139-48
Drug and food interactions
thyroid desiccated food
Applies to: thyroid desiccated
ADJUST DOSING INTERVAL: Consumption of certain foods as well as the timing of meals relative to dosing may affect the oral absorption of T4 thyroid hormone (i.e., levothyroxine). T4 oral absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices. Grapefruit or grapefruit products may delay the absorption of T4 thyroid hormone and reduce its bioavailability. The mechanism of this interaction is not fully understood.
MANAGEMENT: Some manufacturers recommend administering oral T4 as a single daily dose, on an empty stomach, one-half to one hour before breakfast. In general, oral preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals to avoid large fluctuations in serum levels. Foods that may affect T4 absorption should be avoided within several hours of dosing if possible. Consult local guidelines for the administration of T4 in patients receiving enteral feeding.
References (3)
- (2002) "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical
- (2022) "Product Information. Armour Thyroid (thyroid desiccated)." Forest Pharmaceuticals
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
semaglutide food
Applies to: Ozempic (semaglutide)
ADJUST DOSING INTERVAL: Taking oral semaglutide with food, beverage, or other oral medications may alter semaglutide absorption and exposure. In a controlled study with healthy volunteers, limited or no measurable semaglutide exposure was observed in subjects that were fed 30 minutes prior to taking oral semaglutide, while all subjects that fasted overnight and 30 minutes after the oral semaglutide dose had measurable semaglutide exposure. Area under the curve (AUC) and semaglutide peak plasma concentration (Cmax) were approximately 40% greater in subjects that fasted compared to those who did not. AUC and Cmax were also increased with a post-dose fasting period greater than 30 minutes.
MANAGEMENT: It is recommended that oral semaglutide be taken 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water to ensure its efficacy. Fasting longer than 30 minutes after the oral semaglutide dose may lead to increased gastrointestinal side effects including nausea, vomiting, or diarrhea.
References (4)
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Pharmaceuticals Inc
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Canada Inc
- (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Ltd
- Baekdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Sondergaard FL, Borregaard J (2021) "Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation" Diabetes Ther, 12, p. 1915-27
thyroid desiccated food
Applies to: thyroid desiccated
ADJUST DOSING INTERVAL: Concurrent administration of calcium-containing products may decrease the oral bioavailability of levothyroxine by one-third in some patients. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to calcium at acidic pH levels, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. In one study, 20 patients with hypothyroidism who were taking a stable long-term regimen of levothyroxine demonstrated modest but significant decreases in mean free and total thyroxine (T4) levels as well as a corresponding increase in mean thyrotropin (thyroid-stimulating hormone, or TSH) level following the addition of calcium carbonate (1200 mg/day of elemental calcium) for 3 months. Four patients had serum TSH levels that were higher than the normal range. Both T4 and TSH levels returned to near-baseline 2 months after discontinuation of calcium, which further supported the likelihood of an interaction. In addition, there have been case reports suggesting decreased efficacy of levothyroxine during calcium coadministration. It is not known whether this interaction occurs with other thyroid hormone preparations.
MANAGEMENT: Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.
References (4)
- Schneyer CR (1998) "Calcium carbonate and reduction of levothyroxine efficacy." JAMA, 279, p. 750
- Singh N, Singh PN, Hershman JM (2000) "Effect of calcium carbonate on the absorption of levothyroxine." JAMA, 283, p. 2822-5
- Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F (2001) "Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders." Ann Pharmacother, 35, p. 1578-83
- Neafsey PJ (2004) "Levothyroxine and calcium interaction: timing is everything." Home Healthc Nurse, 22, p. 338-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.